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Abstract 
BACKGROUND: Atrial fibrillation contributes to a prothrombotic state through platelet activation. It 
is unclear whether increased platelet aggregability in patients with atrial fibrillation is due to the 
underlying cardiovascular conditions rather than the arrhythmia per se. We investigated the effect of 
postoperative atrial fibrillation (POAF) on platelet reactivity following coronary artery bypass 
grafting (CABG). 
METHODS: The study is a post hoc analysis from a randomized controlled trial NCT01159639 based 
on elective primary CABG patients. Patients were dichotomized depending on POAF. Postoperative 
platelet function testing with arachidonic acid as platelet agonist (ASPI test) was used to define high 
on-aspirin platelet reactivity (HAPR). ΔASPI presented the difference between pre- and postoperative 
ASPI test values. To account for the isolated effect of POAF on platelet reactivity a propensity-score 
analysis was applied.  
RESULTS: Overall incidence of POAF was 23% (92/398). HAPR was detected in 54% (214/398) of 
patients. HAPR was more prevalent amongst POAF when compared to No POAF patients (64.1% 
versus 50.7%; OR 1.74, 95% CI [1.08 – 2.82]; P=0.023). The propensity-score model produced a 
subcohort of patients that were well balanced for comorbidities. POAF when compared to matched 
No POAF group remained more prevalent for HAPR (64.1% versus 45.7%; OR 2.13, 95% CI [1.18 – 
3.85]; P=0.012) and had greater ΔASPI (15.0 [0.0 – 36.0] versus 8.0 [-5.5 – 19.5]; P=0.030). 
CONCLUSIONS: The main finding of our study indicates there is added platelet activation in patients 
with POAF following CABG before and after controlling for pathologies through propensity 
matching. The present study does not prove a causal association between POAF and HAPR.
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Introduction 
In spite of all the prophylactic measures, postoperative atrial fibrillation (POAF) still occurs in about 
15-30% of coronary artery bypass grafting (CABG) patients (1-4). It is associated with increased risk-
adjusted mortality, hospital costs, and readmission rates (4) as well as late mortality (1,2). Proper and 
timely treatment may reduce the risk of stroke and mortality associated with POAF.  
There is a strong correlation between atrial fibrillation (AF) and thromboembolic sequelae. The 
precise mechanism behind the increased thromboembolic risk has not been fully elucidated. 
Abnormalities in cardiac blood flow combined with endothelial disturbances are partly responsible for 
the hypercoagulable state in AF. Other possible mechanisms that have been proposed include 
inflammatory response reaction (5) and neuroendocrine activation (6). Increased expression of platelet 
activation markers has been shown to be associated with AF (7,8).  
There is an excess of platelet activation in AF when compared with healthy control subjects (7), 
although no significant difference between AF patients and disease control subjects in sinus rhythm 
has been established (7). What remains unclear is whether the underlying AF-associated 
cardiovascular conditions, rather than the arrhythmia per se, cause platelet activation noted in those 
patients. The aim of the present study is to determine whether an increase in platelet reactivity might 
be associated with AF following CABG. We hypothesize that an increase of on-aspirin platelet 
reactivity in patients with new-onset POAF is associated with the arrhythmia per se regardless of the 
cardiovascular conditions associated with AF. Data available from a randomized study 
(NCT01159639) were utilized for this post hoc analysis. Although patients that formed the basis for 
this analysis did have underlying AF-associated cardiovascular conditions, pathologies were 
controlled for through propensity matching in order to explain the additional effect of the arrhythmia. 
The disease control group was formed out of subjects without POAF from the matched patient 
subcohort. 
 
Patients and Methods 
The present study is a post hoc analysis from a randomized controlled trial (NCT01159639). It is a 
retrospective analysis of prospectively collected data from a single-center randomized trial. Details of 
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the study design, eligibility, and exclusion criteria have been published previously (9). Briefly, adult 
patients scheduled to undergo elective primary CABG were eligible for the randomized study. On 
postoperative day (POD) 4, patients underwent platelet function testing (PFT). Patients found to have 
high on-aspirin platelet reactivity (HAPR) on POD4 were randomized to 75 mg of clopidogrel and 
300 mg of aspirin, or 300 mg of aspirin. Patients who had adequate platelet reactivity (No HAPR) 
were excluded from the randomized analysis but were included in the follow up. Results comparing 
the incidence of major adverse cardiac and cerebrovascular events (MACCE) at 6 months have 
already been published (10). An exploratory analysis from the randomized trial showing 6-month 
MACCE outcome comparing No HAPR patients to HAPR patients only on aspirin have been 
published more recently (11). For the purpose of this analysis both HAPR and No HAPR patients 
were included and dichotomized to either POAF or No POAF group. 
 
Patients 
All patients were treated with equal antiplatelet therapy during the first 4 days following surgery 
(aspirin 300 mg/day). The only additional exclusion criteria in this analysis not accounted for in the 
original randomized trial is history of previous AF. Flowchart of the study is shown in Figure 1. The 
POAF status in this analysis represents all patients who had a recorded episode of AF lasting for 10 
min or more. Most of these patients were medically converted to sinus rhythm. The POAF status was 
established regardless of medical or spontaneous conversion. 
 
Perioperative Management 
Perioperative management as previously described (9) consisted of our standard hospital protocol for 
elective CABG patients. Preoperative antiplatelet therapy, 100 mg of aspirin was continued up to the 
day of surgery. Clopidogrel in the preoperative period was discontinued 4 to 5 days prior to 
procedure. Patients receiving preoperative beta blockers (B-blocker) were given their normal dose on 
the morning of surgery. Angiotensin-converting enzyme (ACE) inhibitors were discontinued on the 
day of admission, usually two days before the procedure. The anesthetic, intraoperative and early 
postoperative protocols were described in the randomized trial (9).  
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Detection, Prophylaxis and Management of Atrial Fibrillation 
Patients were continuously monitored with telemetry (Nihon Kohden WEP-4208, Tokyo, Japan) until 
POD5. Routine initiation of B-blocker started on POD1 or once inotropic support had been suspended 
with daily dosing escalation. Postoperative medication typically included a B-blocker, a hydroxy-
methyl-glutaryl-CoA reductase inhibitor, proton pump inhibitor for peptic ulcer prophylaxis and a 
diuretic. An ACE-inhibitor was usually not instituted before discharge. Atypical opioid analgesics 
(like Tramadol) were used for pain relief. Non-steroidal anti-inflammatory drugs were generally not 
administered in the early postoperative period. Magnesium and potassium supplements were 
administered to maintain high normal levels. POAF was treated with amiodarone.  
 
Platelet Function Testing  
Blood samples for PFT were obtained on the morning before surgery (POD0) and on POD4 using 
venipuncture. Blood was collected in 4 ml heparin (lithium heparin 68 IU) coated plastic tubes. The 
test was performed 30 minutes after blood sampling. Multiple electrode aggregometry (Multiplate® 
analyzer, Roche Diagnostics International Ltd, Mannheim, Germany) was used. Platelet aggregation, 
as evaluated by multiple electrode aggregometry, accounts for the variability in sensor wire 
impedances (12). Increase in impedance is expressed in arbitrary area under the curve (AUC) units. 
Arachidonic acid (0.5 mM) and adenosine diphosphate (ADP, 6.4 µM) were utilized as platelet 
agonists for conducting the ASPI and ADP tests, respectively. The blood samples were incubated for 
3 min and platelet aggregation was measured 6 min after stimulation with platelet agonist. The ASPI 
test evaluates cyclooxygenase-1-dependent platelet aggregation in response to aspirin. The cut-off 
point for HAPR of patients on aspirin was defined with an ASPI test value exceeding 30 AUC (13). 
This definition was verified using data from another source (14). Change in PFT measurements for 
each patient is presented as delta (Δ), ΔASPI = ASPI POD4 – ASPI POD0 and ΔADP = ADP POD4 – 
ADP POD0. The phenomenon of “aspirin resistance”, a terminology previously used by our group, 
has a wide prevalence in previously published reports (15) with HAPR being more appropriate. 
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Propensity Score Model and Matching 
A number of significant, or near significant, differences were observed between the study groups. 
Such differences confounded the outcome comparisons in observational comparison groups. To 
minimize such confounding variables, we used propensity score matching to derive the risk factor 
matched subcohort. The propensity score represents the probability that a given patient would develop 
POAF. It was derived in a standard fashion for each patient from a logistic multivariate regression 
model that considered POAF status as the dependent outcome variable. Risk factors presented in 
Table 1 were entered in the propensity score calculation model. In order to indicate the level of 
discrimination C-statistic was calculated for the propensity model. Once generated the propensity 
score was employed for propensity-score matching. The algorithm for patient matching consisted of 
single (1-to-1) matching to the nearest counterpart without replacement. After matching, standardized 
mean differences were used to assess the adequacy of matching. A high degree of imbalance was 
reflected by a standardized mean difference of >25%. Differences were displayed for the entire 
unmatched and matched population. After generating risk factor balanced subcohorts through 
propensity-score matching, analysis for estimating the impact of POAF on HAPR was performed.  
 
Statistical Analysis 
Continuous variables are presented as mean ± standard deviation, or median with interquartile range, 
whereas categorical variables are described with frequencies and percentages. Comparisons of POAF 
and No POAF groups before and after matching were performed using the unpaired t test or Mann-
Whitney rank test for continuous, and the Pearson chi-square test for categorical variables. 
Longitudinal comparisons between samples of the same subject were analyzed using the Wilcoxon 
matched pair test. Odds ratios (OR) were used as a measure of the association between POAF and 
HAPR. The respective 95% confidence intervals (CI) were provided. All tests were two-sided and 
statistical significance was set at 5%. Box plots presented in Figure 2 were developed with BoxPlotR, 
a web-tool for generation of box plots (available at http://boxplot.tyerslab.com). Analyses were 
performed using the Statistical Package for Social Sciences software, version 21.0 (IBM, Somers, 
New York, USA). 
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Results 
All patients 
Three hundred and nighty eight patients formed the cohort for this analysis (Figure 1). The incidence 
of POAF was 23% (92/398). PFT on POD4 revealed 54% (214/398) of patients had HAPR. Baseline 
demographic, clinical characteristics and perioperative data of patients before matching are presented 
in Table 1. POAF patients were generally older, more prone to hypertension, hyperlipidemia and 
complex coronary pathology. They also had longer cardiopulmonary bypass duration, higher troponin 
T values on POD1 and lower fibrinogen levels on POD4. Finally, patients with POAF had higher 
incidence of postoperative HAPR (64.1% versus 50.7%; OR 1.74, 95% CI [1.08 – 2.82]; P=0.023). 
There was no difference in preoperative HAPR (POAF versus No POAF; 69.6% versus 65.7%; OR 
1.19, 95% CI [0.72 – 1.97]; P=0.489). 
Results of PFT in relation to surgery and stratified by groups are presented in Table 2. No difference 
was noted in preoperative PFT between groups. POAF patients had higher postoperative ASPI and 
lower ADP test values. When compared to baseline, PFT values on POD4 revealed increased platelet 
activation in POAF and No POAF patients. ΔASPI and ΔADP per group are displayed in Figure 2. 
POAF patients had higher ΔASPI when compared to No POAF (15.0 [0.0 – 36.0] versus 7.5 [-7.0 – 
23.0]; P=0.019). 
 
Propensity-Matched Patients 
A propensity-score model was constructed by adjusting for the variables outlined in Table 1. The 
resulting propensity scores were significantly different (POAF versus No POAF; 0.33±0.15 versus 
0.20±0.14; P<0.000). The corresponding C-statistic value 0.85 (95% CI [0.81 – 0.89]; P<0.001) 
indicates good discrimination. The model produced a subcohort of 184 patients. Overall, 92 patients 
with POAF were matched to 92 without. All of the 25 variables included in the model were well 
balanced, with relatively small standardized mean differences, and no statistically significant 
differences in means (Table 3). In the subcohort analysis patients with POAF had higher incidence of 
postoperative HAPR (64.1% versus 45.7%; OR 2.13, 95% CI [1.18 – 3.85]; P=0.012). There was no 
 8 
difference in preoperative HAPR (POAF versus No POAF; 69.6% versus 64.1%; OR 1.28, 95% CI 
[0.69 – 2.37]; P=0.434). Inverse correlation of postoperative ADP and POAF noted previously was 
not detectable in the matched subcohort while maintaining higher postoperative ASPI test values 
(Table 2). Likewise, POAF patients maintained higher ΔASPI (15.0 [0.0 – 36.0] versus 8.0 [-5.5 – 
19.5]; P=0.030) (Figure 2). 
 
Comment 
The main finding of our study indicates that there is an excess platelet activation in patients with 
POAF regardless of the underlying AF-associated cardiovascular conditions. From the multivariate 
analysis we found that new-onset POAF has an independent association with HAPR in patients 
receiving 300 mg/day of aspirin early after CABG (Online Supplement). Higher preoperative ASPI 
and ADP test values were also independently associated with postoperative HAPR showing consistent 
PFT analysis results with the Multiplate® analyzer. In order to account for the underlying AF-
associated cardiovascular conditions we controlled for pathologies through propensity matching. The 
propensity-matched analysis corroborated a subcohort of patients that were well-balanced for 
comorbidities. From matched patient analysis higher postoperative ASPI test values and a greater 
increase in platelet reactivity was demonstrated through ΔASPI in on-treatment POAF patients when 
compared to those without POAF thus confirming our hypothesis. To our knowledge this is the first 
study to assess and show a correlation between AF and platelet function with multiple electrode 
aggregometry and Multiplate® analyzer.  
It is a well-known fact that platelet activation is strongest at the location of vascular intimal injury and 
is essential in the process of thrombus formation. Patients with AF and thrombus formations have 
increased plasma concentrations of markers of platelet activation and thrombogenesis, as well as 
evidence of endothelial dysfunction (16).  Platelet surface expression of CD62P (P-selectin) is 
enhanced in activated platelets, while soluble P-selectin is a plasma marker of platelet activation (17). 
However, studies of soluble P-selectin levels in AF have shown conflicting results. Within 12 hours of 
arrhythmia onset patients with paroxysmal AF have detectable P-selection levels (18). While excess 
platelet activation in AF compared with healthy control subjects is significant, no significant 
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difference between AF patients and disease control subjects in sinus rhythm was detected (7). When 
considering the findings from the study of Choudhury et al we performed the present analysis and 
found that new-onset POAF is independently associated with HAPR in patients following CABG. 
Platelet activity measured from peripheral blood samples is enhanced in the setting of paroxysmal AF 
after 3 to 12 hours (18,19). Return to “normal” levels of platelet activity can be detected 24 hours 
after successful cardioversion (19). Due to the lack of data describing the time point when POAF 
occurred after CABG in our analysis, one could argue against our hypothesis of an association 
between POAF and HAPR. When analyzing the available data on the time association of POAF and 
open-heart surgery, most reports indicate the highest incidence within the first 4 days following the 
procedure, peaking around the second day (3,20). Therefore, if the timing of postoperative PFT was 
synchronized with the timing of POAF, the association effect of POAF and HAPR could only have 
been stronger.  
Pathogenesis of POAF might be explained by increased inflammatory activity and endothelial 
dysfunction. Significant associations between dense spontaneous echo contrast and the 2 indexes, C-
reactive protein and soluble P-selection, support the hypothesis of increased inflammatory activity for 
thrombogenesis in AF (5). Inflammatory markers play an important role in the development of AF, 
although the results are not consistent (3). An association of preoperative platelet activity and POAF 
has been shown previously (21,22). In the study of Antoniades et al preoperative soluble CD40 ligand 
level, a marker of platelet activation was found to be a risk factor for POAF independent of systemic 
endothelial function, vascular redox state, and systemic inflammation in patients undergoing off-pump 
coronary bypass surgery.  
ACE-inhibitors have been shown to have a beneficial clinical outcome in patients with AF for 
hypertension treatment (23). The renin-angiotensin-aldosterone system could be mechanistically 
implicated in the initiation and perpetuation of atrial fibrillation, as well as providing the link to other 
mechanisms promoting the prothrombotic state in atrial fibrillation (24). Interestingly, the results of 
our analysis also illustrated that long-term preoperative ACE-inhibitor therapy has an inverse 
correlation with early postoperative HAPR in the setting of an elective CABG population. 
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Dual antiplatelet therapy with aspirin and thienopyridines reduces the risk of ischemic events in 
patients with acute coronary syndrome (25,26). However, it was shown not to be more effective than 
aspirin alone among patients with stable cardiovascular disease in a broader population of patients 
(27). While pronounced platelet inhibition reduces the risk of ischemic events it comes at a cost of 
moderate-to-sever bleeding (25-27). Clopidogrel and aspirin versus aspirin alone, showed to be 
beneficial in reducing the rate of major vascular events among patients with AF who were unsuitable 
for vitamin K antagonists (28). Considering the beneficial effect shown with stronger platelet 
inhibition in the ACTIVE A trial (28) and the association of POAF and HAPR we found in the 
present analysis, forthcoming larger longitudinal trials might reveal the potential clinical benefit of 
PFT tailored antiplatelet therapy in CABG patients with POAF. 
Some limitations of this study should be noted. First, it is subject to limitations inherent to any 
retrospective analysis. The present study does not prove a causal association between POAF and 
HAPR. We used ECG and telemetry monitoring to detect POAF and did not use ECG-Holter 
monitoring. Duration and timing of POAF were not documented and therefore the effect could not be 
analyzed. The small sample size gives little room to address the clinical implications of the results. 
Platelet response to aspirin is also influenced by other unaccounted factors such as concomitant 
therapy and genotype. Genetic testing was not part of the protocol in the NCT01159639 trial. Even 
though there is no evidence linking amiodarone to increased platelet aggregability, the lack of 
consideration of treatment affect, particularly amiodarone is another limitation in our study.  
In summary, there is an independent association of new-onset POAF and an additional excess platelet 
activation in patients following CABG, regardless of the underlying AF-associated cardiovascular 
conditions. Considering that various markers involved in the inflammatory hypothesis for 
thrombogenesis in AF play a key role in the etiology of arrhythmia it is hard to explain the cause-and-
effect association between arrhythmia burden and platelet activation. Partial understanding of 
mechanisms underlying AF-induced thrombogenesis requires further research. To establish whether 
platelet activation is the key feature in the mechanism of POAF thrombogenesis, it will be important 
for future studies to include other more specific measures of platelet activity and to account for other 
factors in the process of AF-induced thrombus formation. 
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Table 1. Baseline demographic, clinical characteristics and perioperative data of patients before 
propensity matching stratified by postoperative atrial fibrillation 
 No POAF (n=306) POAF (n=92) P-value Std. Diff. (%) 
Age (years) 62.9±8.7 67.1±7.1 <0.001 58.1 
Male gender 234 (76%) 75 (82%) 0.308 12.9 
BMI (kg/m2) 28.8±4.1 29.2±4.2 0.494 9.0 
EuroSCORE (%) 3.2±3.1 3.3±2.5 0.221 2.4 
LVEF (%) 55±11 55±9 0.895 0.9 
Hyperlipidemia 287 (94%) 91 (99%) 0.049 49.1 
Diabetes mellitus 108 (35%) 33 (36%) 0.919 1.2 
Hypertension 291 (95%) 92 (100%) 0.030 inf 
Chronic kidney disease* 11 (4%) 7 (8%) 0.104 15.1 
Smoker 122 (40%) 28 (30%) 0.102 -20.4 
Left main narrowing 125 (41%) 44 (48%) 0.235 13.9 
Three-vessel disease 222 (73%) 77 (84%) 0.030 30.0 
Preoperative medication 
Statin 286 (93%) 90 (98%) 0.108 29.7 
Aspirin 276 (90%) 85 (92%) 0.525 8.2 
B-blocker 247 (81%) 79 (86%) 0.260 14.7 
ACE-inhibitor 212 (69%) 66 (72%) 0.652 5.4 
Clopidogrel 94 (31%) 26 (28%) 0.652 -5.4 
Perioperative data 
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LIMA use 288 (94%) 84 (91%) 0.338 -9.9 
X-clamp time (min) 55±20 60±24 0.082 17.5 
CPB time (min) 83±25 91±29 0.006 30.4 
Ventilation time (h) 8.0 (6.0-11.0) 8.5 (7.0-12.8) 0.171 20.7 
Postoperative inotropes 86 (28%) 30 (33%) 0.405 9.6 
Tropononin T POD1 (µg/L) 0.54 (0.32-0.90) 0.63 (0.40-1.40) 0.023 21.0 
Hematocrit POD4 (%) 28±4 27±3 0.123 -23.4 
Fibrinogen POD4 (g/L) 6.9±1.4 6.6±1.5 0.029 -21.3 
ACE-inhibitor=angiotensin-converting enzyme inhibitor; B-blocker=beta blocker; BMI=body mass 
index; CPB=cardiopulmonary bypass; EuroSCORE=European System for Cardiac Operative Risk 
Evaluation; HAPR=high on-aspirin platelet reactivity; inf=infinity; LIMA=left internal mammary 
artery; LVEF=left ventricular ejection fraction; POAF=postoperative atrial fibrillation; 
POD=postoperative day; Std. Diff.=standardized mean difference, X-clamp=aortic cross-clamp 
* Chronic kidney disease was defined as preoperative serum creatinine >200 µmol/L or renal 
replacement therapy 
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Table 2. Platelet function testing 
 All patients Matched patients 
No POAF POAF P-value No POAF POAF P-value 
ASPI POD0 31±26 28±26 0.263 30±25 28±26 0.602 
ADP POD0 75±28 70±25 0.074 72±28 70±25 0.622 
ASPI POD4 38±27 43±27 0.033 36±29 43±27 0.010 
ADP POD4 93±35 82±33 0.006 85±37 82±33 0.478 
P-valuea <0.001 <0.001  0.009 <0.001  
P-valueb <0.001 <0.001  0.003 <0.001  
ADP=adenosine diphosphate dependent platelet aggregation; ASPI=cyclooxygenase dependent 
platelet aggregation; POAF=postoperative atrial fibrillation; POD=postoperative day  
a P-value for ASPI POD0 versus ASPI POD4 
b P-value for ADP POD0 versus ADP POD4 
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Table 3. Baseline demographic, clinical characteristics and perioperative data of patients after 
propensity matching stratified by postoperative atrial fibrillation 
 No POAF (n=92) POAF (n=92) P-value Std. Diff. (%) 
Age (years) 66.7±7.5 67.1±7.1 0.717 5.5 
Male gender 79 (86%) 75 (82%) 0.425 -11.1 
BMI (kg/m2) 29.2±4.4 29.2±4.2 0.846 0.4 
EuroSCORE (%) 3.3±2.6 3.3±2.5 0.883 -0.6 
LVEF (%) 54±10 55±9 0.932 3.7 
Hyperlipidemia 89 (97%) 91 (99%) 0.312 20.9 
Diabetes mellitus 30 (33%) 33 (36%) 0.641 6.8 
Hypertension 92 (100%) 92 (100%) 1.000 NaN 
Chronic kidney disease* 8 (9%) 7 (8%) 0.788 -4.1 
Smoker 29 (32%) 28 (30%) 0.873 -2.3 
Left main narrowing 44 (48%) 44 (48%) 1.000 0.0 
Three-vessel disease 78 (85%) 77 (84%) 0.840 -2.9 
Preoperative medication 
Statin 89 (97%) 90 (98%) 0.650 7.4 
Aspirin 84 (91%) 85 (92%) 0.788 4.1 
B-blocker 74 (80%) 79 (86%) 0.325 15.5 
ACE-inhibitor 65 (71%) 66 (72%) 0.871 2.4 
Clopidogrel 31 (34%) 26 (28%) 0.425 -12.0 
Perioperative data 
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LIMA use 84 (91%) 84 (91%) 1.000 0.0 
X-clamp time (min) 58±21 60±24 0.833 4.8 
CPB time (min) 91±28 91±29 0.933 1.3 
Ventilation time (h) 8.0 (7.0-10.5) 8.5 (7.0-12.8) 0.440 20.5 
Postoperative inotropes 25 (27%) 30 (33%) 0.421 11.5 
Tropononin T POD1 (µg/L) 0.60 (0.32-1.00) 0.63 (0.40-1.40) 0.372 5.0 
Hematocrit POD4 (%) 0.27±0.03 0.27±0.03 0.812 -3.7 
Fibrinogen POD4 (g/L) 6.7±1.4 6.6±1.5 0.305 -7.7 
ACE-inhibitor=angiotensin-converting enzyme inhibitor; B-blocker=beta blocker; BMI=body mass 
index; CPB=cardiopulmonary bypass; EuroSCORE=European System for Cardiac Operative Risk 
Evaluation; HAPR=high on-aspirin platelet reactivity; LIMA=left internal mammary artery; 
LVEF=left ventricular ejection fraction; NaN=number not available; POAF=postoperative atrial 
fibrillation; POD=postoperative day; Std. Diff.=standardized mean difference, X-clamp=aortic cross-
clamp 
* Chronic kidney disease was defined as preoperative serum creatinine >200 µmol/L or renal 
replacement therapy 
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Figure legends 
Figure 1. Study flowchart showing patient eligibility and study protocol. Previous publications from 
the same trial (NCT01159639) have likewise been noted. AF=atrial fibrillation; CABG=coronary 
artery bypass grafting; dAPT=dual antiplatelet therapy; HAPR=high on-aspirin platelet reactivity; 
MI=myocardial infarction; PCI=percutaneous coronary intervention; PFT=platelet function testing; 
POAF=postoperative atrial fibrillation; POD=postoperative day, PVD=peripheral vascular disease; 
TEA=thrombendarterectomy.  
Figure 2. Box-and-whisker plots showing differences (ΔASPI and ΔADP) between preoperative and 
postoperative platelet function measurements for all and propensity-matched subcohort of patients 
stratified according to postoperative atrial fibrillation (POAF) status. ADP=adenosine diphosphate 
dependent platelet aggregation; ASPI=cyclooxygenase dependent platelet aggregation; AUC=area 
under the curve; POAF=postoperative atrial fibrillation. 
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Abbreviations 
ACE – angiotensin-converting enzyme 
ADP – adenosine diphosphate dependent platelet aggregation 
AF – atrial fibrillation 
ASPI – cyclooxygenase dependent platelet aggregation  
AUC – area under the curve 
CABG – coronary artery bypass grafting 
HAPR – high on-aspirin platelet reactivity 
CI – confidence interval 
MACCE – major adverse cardiac and cardiovascular event 
OR – odds ratio 
PFT – platelet function testing 
POAF – postoperative atrial fibrillation 
POD – postoperative day 
Δ – delta  


Multivariate logistic regression 
Stepwise multivariate logistic regression analysis was performed to assess independence of correlation 
between POAF and postoperative HAPR. Postoperative HAPR status was the dependent variable in the 
multivariate regression analysis. Variables presented in Supplement Table 2 were included as independent 
variables in the multivariate regression analysis. For multivariate regression, variables with a probability 
value of >0.1 were removed. Odds ratios (OR) were used as a measure of the association between 
independent variables and HAPR. The respective 95% confidence intervals (CI) were provided. 
Multivariate logistic regression analysis with postoperative HAPR status as the dependent variable 
showed an independent association with POAF (overall model R2=0.297, P<0.001).  
 
Supplement Table 1. Multivariate logistic regression analysis results showing predictors of postoperative 
high on-aspirin platelet reactivity (all patients, N = 398) 
 OR 95% CI P Value 
Age (years) 1.05 1.02 – 1.08 0.002 
Left main narrowing 1.73 1.09 – 2.75 0.020 
POAF 1.81 1.04 – 3.15 0.035 
Preoperative medication 
ACE-inhibitor 0.18 0.11 – 0.31 <0.001 
Statin 5.93 1.97 – 17.84 0.002 
Preoperative platelet function testing (POD 0) 
ASPI test values (AUC) 1.02 1.01 – 1.03 <0.001 
ADP test values (AUC) 1.01 1.00 – 1.02 0.026 
ACE-inhibitor=angiotensin-converting enzyme inhibitor; ADP=adenosine diphosphate dependent platelet 
aggregation; ASPI=cyclooxygenase dependent platelet aggregation; CI=confidence interval; OR=odds 
ratio; POAF=postoperative atrial fibrillation; POD=postoperative day 
 Supplement Table 2. Baseline demographic, clinical characteristics and perioperative data of patients 
stratified by high on-aspirin platelet reactivity 
 No HAPR (n=184) HAPR (n=214) P Value 
Age (years) 62.7±8.1 64.9±8.8 0.012 
Male gender 148 (80%) 161 (75%) 0.214 
BMI (kg/m2) 28.6±4.3 29.2±3.9 0.158 
EuroSCORE (%) 2.8±2.3 3.6±3.4 0.011 
LVEF (%) 54.8±10.5 54.4±10.3 0.775 
Hyperlipidemia 172 (93%) 206 (96%) 0.205 
Diabetes mellitus 64 (35%) 77 (36%) 0.803 
Hypertension 178 (97%) 205 (96%) 0.622 
Chronic kidney disease* 6 (3%) 12 (6%) 0.261 
Smoker 71 (39%) 79 (37%) 0.732 
Left main narrowing 66 (36%) 103 (48%) 0.014 
Three-vessel disease 135 (73%) 164 (77%) 0.452 
Preoperative platelet function testing (POD 0) 
ASPI test values (AUC) 23.8±20.6 35.6±28.7 <0.001 
ADP test values (AUC) 68.5±27.9 78.8±25.9 <0.001 
Preoperative medication 
Statin 168 (91%) 208 (97%) 0.010 
Aspirin 170 (92%) 191 (89%) 0.282 
B-blocker 148 (80%) 178 (83%) 0.478 
ACE-inhibitor 156 (85%) 122 (57%) <0.001 
Clopidogrel 58 (32%) 62 (29%) 0.581 
Perioperative data 
LIMA use 172 (94%) 200 (93%) 0.993 
X-clamp time (min) 55.1±20.8 57.3±21.1 0.147 
CPB time (min) 82.5±27.1 86.4±26.0 0.078 
Ventilation time (h) 9.9±9.7 10.5±6.9 0.021 
Postoperative inotropes 49 (27%) 67 (31%) 0.306 
Tropononin T POD 1 (µg/L) 0.54 (0.31 – 0.90) 0.60 (0.35 – 1.11) 0.203 
Hematocrit POD 4 (%) 0.28±0.03 0.28±0.03 0.820 
Fibrinogen POD 4 (g/L) 6.9±1.6 6.8±1.4 0.514 
Postoperative platelet function testing (POD 4) 
ASPI test values (AUC)a 20.1±6.3 56.3±26.1 <0.001 
ADP test values (AUC)a 84.8±35.9 95.3±32.4 0.002 
ACE-inhibitor=angiotensin-converting enzyme inhibitor; ADP=adenosine diphosphate dependent platelet 
aggregation; ASPI=cyclooxygenase dependent platelet aggregation; AUC=area under the curve; B-
blocker=beta blocker; BMI=body mass index; CPB=cardiopulmonary bypass; EuroSCORE=European 
System for Cardiac Operative Risk Evaluation; HAPR=high on-aspirin platelet reactivity; LIMA=left 
internal mammary artery; LVEF=left ventricular ejection fraction; POD=postoperative day; X-
clamp=aortic cross-clamp 
* Chronic kidney disease was defined as preoperative serum creatinine >200 µmol/L or renal replacement 
therapy 
a Not included in the multivariate logistic regression analysis 
 
